SonicStrategy Inc. has staked a total of 141.9 million Sonic tokens across two validators, including 127.2 million tokens held by the company itself, valued at about CAD $6.8 million. The staking generates annual rewards estimated at 7.6 million Sonic tokens, worth approximately CAD $408,000, supporting the company's operations and growth. This activity enhances the security and participation of the Sonic blockchain network, reflecting SonicStrategy's commitment to long-term infrastructure development. The company continues to maintain reliable validator operations with support from Sonic Labs and plans to sustain its role in the ecosystem.
SonicStrategy's staking activity is the subject, with Pluang market data providing context. For readers following US stocks, here is Pluang's market snapshot as of Sep 21, 2026 19:32 WIB: Out of 150 priced US stocks, 121 rose and 25 fell. Notable movers include HPQ at USD 32.70 with a -4.94% change and a typical hold time of 69 days, ACN at USD 188.00 with a +3.70% change and a typical hold time of 132 days, and LI at USD 11.71 with a -3.54% change and a typical hold time of 100 days.
On September 21, 2026, Sandisk was added to the S&P 100 index, replacing Nike, which was removed on the same day. This change reflects shifts in market capitalization and company performance within the index. The update is significant for investors t...
Several top analysts, including Cantor Fitzgerald, Guggenheim, Morgan Stanley, and BTIG Research, have raised price targets and upgraded their outlooks for ServiceNow, signaling confidence in the company's long-term growth. Despite this, the stock ha...
Piper Sandler lowered Colgate-Palmolive's price target to $95 due to weak North American demand and rising competition. The company is responding by focusing on premium oral care innovations, expanding the Fabuloso line, increasing advertising, and c...
MillerKnoll is set to report Q3 2026 earnings with analysts expecting $0.35 EPS and $940.93 million in revenue. The North America Contract segment shows strength with higher prices and volumes, while the Global Retail segment struggles due to tariffs...
Faruqi & Faruqi, LLP is investigating claims against Ardelyx for allegedly misleading investors about the commercial performance of its drugs XPHOZAH and IBSRELA. The lawsuit alleges Ardelyx failed to disclose increasing payer restrictions that hurt ...
